文献速递心力衰竭与心肌病

阻止JP2的calpain位点特异性切割可预防应激诱导的兴奋-收缩耦联脱耦联和心力衰竭发展

Preventing Site-Specific Calpain Proteolysis of Junctophilin-2 Protects Against Stress-Induced Excitation-Contraction Uncoupling and Heart Failure Development.
PubMed 文献 · Circulation · 2024-09-18

本研究通过构建抗calpain切割的JP2敲入小鼠(JP2CR),在 transverse aortic constriction(TAC)模型中评估阻止JP2位点特异性calpain切割对心脏的保护作用。结果表明JP2CR小鼠对压力负荷应激更具抵抗力,Ca2+稳态和T管组织显著改善,心脏功能障碍、肥厚、肺水肿、纤维化和基因表达改变均显著减轻。在已发生心脏功能障碍的小鼠中,JP2CR基因治疗可减缓心衰进展且优于野生型JP2。

要点

  • JP2的calpain位点特异性切割是应激诱导E-C耦联破坏和心衰发展的关键环节。
  • JP2CR敲入小鼠在TAC后心脏功能、结构及Ca2+稳态均显著优于野生型。
  • JP2CR基因治疗在心脏功能障碍发生后仍可减缓心衰进展,且优于野生型JP2。

核心结论

  • 阻止JP2的calpain位点特异性切割可提供多重心脏保护效应,对抗应激诱导的蛋白水解、肥厚和心衰。
  • 靶向JP2主要calpain切割位点的基因治疗有望成为治疗心衰的新型精准医学策略。

研究设计与样本

  • 研究构建了删除JP2主要calpain切割位点的抗calpain切割JP2敲入小鼠(JP2CR)。
  • 在体外切割实验和1 μmol/L异丙肾上腺素处理的分离心肌细胞中评估JP2切割。
  • 在TAC术后5周比较野生型和JP2CR小鼠与假手术组的心脏结局,采用超声心动图、组织学和RNA测序。
  • 在已建立心脏功能障碍的小鼠中评估AAV介导的JP2CR、JP2或GFP基因治疗减缓心衰进展的效果。

主要发现

  • JP2CR心肌细胞中calpain对JP2的蛋白水解以及TAC和异丙肾上腺素诱导的JP2切割被阻断。
  • JP2CR心脏对压力负荷应激更具抵抗力,Ca2+稳态和T管组织显著改善。
  • JP2CR小鼠TAC后心脏功能障碍、肥厚、肺水肿、纤维化和基因表达改变相对野生型显著减轻。
  • JP2CR通过减弱TAC诱导的calpain活性增加,保持calpain敏感性E-C耦联相关蛋白(包括RyR2、CaV1.2和SERCA2a)的完整性。
  • 心脏功能障碍发生后给予JP2CR基因治疗可有效减缓心衰进展,且优于野生型JP2。

临床怎么用

  • JP2的calpain位点特异性切割可作为心衰精准治疗的新靶点。
  • JP2CR基因治疗在心脏功能障碍发生后仍有效,提示其用于心衰二级预防的潜力。

局限性

  • 研究主要基于小鼠模型,结论向人类临床转化尚需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Excitation-contraction (E-C) coupling processes become disrupted in heart failure (HF), resulting in abnormal Ca2+ homeostasis, maladaptive structural and transcriptional remodeling, and cardiac dysfunction. Junctophilin-2 (JP2) is an essential component of the E-C coupling apparatus but becomes site-specifically cleaved by calpain, leading to disruption of E-C coupling, plasmalemmal transverse tubule degeneration, abnormal Ca2+ homeostasis, and HF. However, it is not clear whether preventing site-specific calpain cleavage of JP2 is sufficient to protect the heart against stress-induced pathological cardiac remodeling in vivo. METHODS: Calpain-resistant JP2 knock-in mice (JP2CR) were generated by deleting the primary JP2 calpain cleavage site. Stress-dependent JP2 cleavage was assessed through in vitro cleavage assays and in isolated cardiomyocytes treated with 1 μmol/L isoproterenol by immunofluorescence. Cardiac outcomes were assessed in wild-type and JP2CR mice 5 weeks after transverse aortic constriction compared with sham surgery using echocardiography, histology, and RNA-sequencing methods. E-C coupling efficiency was measured by in situ confocal microscopy. E-C coupling proteins were evaluated by calpain assays and Western blotting. The effectiveness of adeno-associated virus gene therapy with JP2CR, JP2, or green fluorescent protein to slow HF progression was evaluated in mice with established cardiac dysfunction. RESULTS: JP2 proteolysis by calpain and in response to transverse aortic constriction and isoproterenol was blocked in JP2CR cardiomyocytes. JP2CR hearts are more resistant to pressure-overload stress, having significantly improved Ca2+ homeostasis and transverse tubule organization with significantly attenuated cardiac dysfunction, hypertrophy, lung edema, fibrosis, and gene expression changes relative to wild-type mice. JP2CR preserves the integrity of calpain-sensitive E-C coupling-related proteins, including ryanodine receptor 2, CaV1.2, and sarcoplasmic reticulum calcium ATPase 2a, by attenuating transverse aortic constriction-induced increases in calpain activity. Furthermore, JP2CR gene therapy after the onset of cardiac dysfunction was found to be effective at slowing the progression of HF and superior to wild-type JP2. CONCLUSIONS: The data presented here demonstrate that preserving JP2-dependent E-C coupling by prohibiting the site-specific calpain cleavage of JP2 offers multifaceted beneficial effects, conferring cardiac protection against stress-induced proteolysis, hypertrophy, and HF. Our data also indicate that specifically targeting the primary calpain cleavage site of JP2 by gene therapy approaches holds great therapeutic potential as a novel precision medicine for treating HF.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Wang, Chen, Shi, et al. Preventing Site-Specific Calpain Proteolysis of Junctophilin-2 Protects Against Stress-Induced Excitation-Contraction Uncoupling and Heart Failure Development. Circulation. 2024. PMID: 39291390. doi:10.1161/CIRCULATIONAHA.124.069329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。